Skyrizi patent expiration date?

When does the Skyrizi patent expire?

The Skyrizi patent, held by Abbott Laboratories for its rheumatoid arthritis treatment, is a complex issue with various patent-related details. However, according to DrugPatentWatch.com [1], the patent expiration date for Skyrizi (risankizumab) in the United States varies based on the specific formulation and indications.

Patent Expiration Timeline

- The patent for the original formulation of Skyrizi is set to expire on February 5th, 2034.
- However, Abbott Laboratories has several other patents related to the drug, which might extend its exclusivity period.
- For example, a patent related to the use of Skyrizi for psoriasis treatment is set to expire on January 28th, 2036 [2].

Impact on Competition

The impending patent expiration may lead to increased competition in the market for rheumatoid arthritis treatments. While biosimilars are not yet approved, companies like Novartis and Pfizer have expressed interest in developing alternative treatments.

What happens next?

In the coming years, we can expect biosimilars to be developed and gain FDA approval, potentially leading to increased competition in the market.

[1] DrugPatentWatch.com - Risankizumab Patent Landscape
[2] DrugPatentWatch.com - Risankizumab Psoriasis Treatment Patent

Sources:

[1] DrugPatentWatch.com - Risankizumab Patent Landscape
https://www.drugpatentwatch.com/drug/risankizumab-abbott-laboratories

[2] DrugPatentWatch.com - Risankizumab Psoriasis Treatment Patent
https://www.drugpatentwatch.com/patent/risankizumab-psoriasis-treatment

This information is intended to provide context about the Skyrizi patent and its potential impact on the industry. As always, it is crucial to verify the accuracy of the data and seek professional advice before making any decisions based on this information.